

CURRICULUM VITAE

CARLO ALESSANDRIA

Surname: ALESSANDRIA
Name: CARLO
Date of birth: January 6th 1974
Luogo di nascita: Turin
Nazionalità: Italian

Degree:

Medicine and Surgery
UNIVERSITY OF TURIN, 1999

Specialty:

Gastroenterology and Digestive Endoscopy
UNIVERSITY OF TURIN, 2003

Present appointment:

- Staff clinician from June 2007, Division of Gastroenterology, A.O.U. Città della Salute e della Scienza di Torino, Corso Bramante 88, 10126 Turin, Italy
- National scientific qualification for Associate Professor in "MALATTIE DELL'APPARATO DIGERENTE" from 18/09/2019

Fellowships:

Fellowship in hepatology (2002-2003), University of Barcelona, Hospital Clínic i Provincial de Barcelona – "Pathophysiology and treatment of ascites and renal dysfunction in liver cirrhosis" (Prof. Vicente Arroyo, Prof. Pere Ginès).

Memberships:

- Ordine dei Medici (Italy)
- Member of the Italian Association for the study of the liver (AISF)
- Member of the European Association for the study of the liver (EASL)

Prizes:

AISF (Italian Association for the Study of the Liver) prize for "Best clinical communication". Alessandria C, Mezzabotta L, Carello M, Debernardi-Venon W, Martini S, Rizzetto M, Marzano A. "Relative adrenal insufficiency in cirrhosis: Relevance in patients with ascites and treatment with hydrocortisone in refractory ascites". Rome, AISF Congress, 2009.

Major publications

H-index (according to Scopus): 32 (March 2023)

Number of citations (according to Scopus): 6737 (March 2023)

Original papers

1. Gaia S, **Alessandria C**, Marzano A, Rizzetto M. Polycystic Liver Disease. Liver Transpl 2001; 7(10):912.
2. Debernardi-Venon W, Barletti C, **Alessandria C**, Marzano A, Baronio M, Todros L, Saracco G, Rizzetto M. Efficacy of Irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci 2002; 47: 401-404.
3. **Alessandria C**, Debernardi-Venon W, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal síndrome type 2. Eur J Gastroenterol Hepatol 2002; 14(12):1363-8.
4. Restuccia T, Ortega R, Guevara M, Ginès P, **Alessandria C**, Ozdogan O, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Rodés J. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40 (1): 140-6.
5. Guevara M, **Alessandria C**, Uriz J. Transjugular intrahepatic portosystemic shunt and refractory ascites. Gastroenterol Hepatol 2004; 27 (4): 285-91.
6. **Alessandria C**, Gaia S, Marzano A, Debernardi Venon W, Fadda M, Rizzetto M. Application of the Model for End-Stage Liver Disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 2004; 16 (6): 607-12.
7. Restuccia T, Gómez-Ansón B, Guevara M, **Alessandria C**, Torre A, Terra C, Martín M, Castellví M, Rami L, Sainz A, Ginès P, Arroyo V. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 2004; 39 (6): 1613-22.
8. Guevara M, Fernandez-Esparrach G, **Alessandria C**, Torre A, Terra C, Montana X, Piera C, Alvarez ML, Jiménez W, Ginès p, Arroyo V. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 2004; 40 (3): 646-51.
9. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, **Alessandria C**, Franchello A, Salizzoni M, Rizzetto M. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11 (4): 402-409.
10. **Alessandria C**, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, Rodés J, Ginès P. MELD score and clinical type predict prognosis in hepatorenal syndrome. Relevance to liver transplantation. Hepatology 2005; 41 (6): 1282-9.
11. Ceretto S, **Alessandria C**, Rizzetto M, Marzano A. Bacterial overgrowth in intestinal lipomatosis with pandidiverticulosis. Clin Gastroenterol Hepatol 2007 Jul;5(7):A30.
12. Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, **Alessandria C**, Bonardi R, Saracco G, Rizzetto M, Marzano A. AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46(6):1026-33.
13. **Alessandria C**, Ottobrelli A, Debernardi-Venon W, Todros L, Torrani Cerenzia M, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin versus terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47(4):499-505.
14. **Alessandria C**, Debernardi-Venon W, Rizzetto M, Marzano A. Transjugular liver biopsy: a relatively simple procedure with an indefinite past and an expected brilliant future. J Hepatol 2008; 48(1):171-172.
15. Marzano A, **Alessandria C**, Rizzetto M. Definition of hepatitis B infection for the best practice in chronic disease and in immunosuppressed patients. J Hepatol 2008; 48(3):515-16.
16. Gaia S, Barbon, Smedile A, Olivero A, Carenzi S, Lagget M, **Alessandria C** et al. Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol. 2008 Apr;48(4):540-7.
17. **Alessandria C**, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. Dig Liver Dis 2009; 41 298-302.
18. **Alessandria C**, Elia C, Mezzabotta L, Riso A, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standars vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis 2011; 43 (11): 881-6.

19. Marzano A, Marengo A, Ruggiero T, Alice T, Sanna C, **Alessandria C**, Morgando A, Sciandrello MC, Franzin AM, Rizzetto M, Ghisetti V. Clinical impact of A/H1/N1/09 influenza in patients with cirrhosis: experience from a nosocomial cluster of infection. J Med Virol. 2013; 85 (1): 1-7.
20. Angeli P, Sanyal A, Moeller S, **Alessandria C** et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int. 2013; 33 (1): 16-23.
21. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, **Alessandria C**, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-Chronic Liver Failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (7): 1426-37.
22. Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, Pereira G, Poca M, Sánchez J, Guevara M, Soriano G, **Alessandria C**, Fernández J, Arroyo V, Ginès P. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014; 60(5):955-61.
23. Jalan R, Saliba F, Pavesi M, Amorós A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, **Alessandria C**, Rodríguez E, Solís-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V; CANONIC study investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014; 61(5): 1038-47.
24. Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Ginès P, Durand F, Angeli P, **Alessandria C**, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V; CANONIC Study Investigators; EASL-CLIF Consortium. The CLIF Consortium Acute Decompensation score (CLIF-CADs) for prognosis in hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2015; 62 (4): 831-40.
25. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, **Alessandria C**, Laleman W, Trebicka J, Elkrief L, Hopf C, Solís-Munoz P, Saliba F, Zeuzem S, Albillos A, Benten D, Montero-Alvarez JL, Chivas MT, Concepción M, Córdoba J, McCormick A, Stauber R, Vogel W, de Gottardi A, Welzel TM, Domenicali M, Risso A, Wendon J, Deulofeu C, Angeli P, Durand F, Pavesi M, Gerbes A, Jalan R, Moreau R, Ginés P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62(1):243-52.
26. Risso A, **Alessandria C**, Mezzabotta L, Elia C, Andrealli A, Spandre M, Di Luigi P, Barbui A, Evangelista A, Morgando A, Serra R, Ciccone G, Marzano A, Rizzetto M. Adrenal function and microbial DNA in noninfected cirrhotic patients with ascites. Relationship and effect on survival. Dig Liver Dis. 2015 Aug;47(8):702-8.
27. Italian Association for the Study of the Liver (AISF); Italian Society of Transfusion Medicine and Immunohaematology (SIMTI); Italian Association for the Study of the Liver AISF; Italian Society of Transfusion Medicine and Immunohaematology SIMTI. AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. Dig Liver Dis. 2016 Jan;48(1):4-15.
28. Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, **Alessandria C**, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel TM, Albillos A, Gustot T, Benten D, Durand F, Ginès P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF). Systemic inflammation in decompensated cirrhosis. Characterization and role in acute-on-chronic liver failure. Hepatology. 2016 Oct;64(4):1249-64.
29. Piano S, Schmidt HH, Ariza X, Amorós A, Romano A, Hüsing-Kabar A, Solà E, Gerbes A, Bernardi M, **Alessandria C**, Scheiner B, Tonon M, Maschmeier M, Solà C, Trebicka J, Gustot T, Nevens F, Arroyo V, Gines P, Angeli P; EASL CLIF Consortium, European Foundation for the Study of Chronic Liver Failure (EF Clif). Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 Nov; 16(11):1792-1800
30. Champion D, Ponzo P, **Alessandria C**, Saracco GM, Balzola F. Role of microbiota in the autism spectrum disorders.. Minerva Gastroenterol Dietol. 2018 Dec; 64(4):333-350.

31. Caraceni P, Riggio O, Angeli P, **Alessandria C** et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet*. 2018 Jun 16;391(10138):2417-2429.
32. Fernández J, Prado V, Trebicka J, Amorós A, Gustot T, Wiest R, Deulofeu C, Garcia E, Acevedo J, Fuhrmann V, Durand F, Sánchez C, Papp M, Caraceni P, Vargas V, Bañares R, Piano S, Janicko M, Albillos A, **Alessandria C**, Soriano G, Welzel TM, Laleman W, Gerbes A, De Gottardi A, Merli M, Coenraad M, Saliba F, Pavesi M, Jalan R, Ginès P, Angeli P, Arroyo V; European Foundation for the Study of Chronic Liver Failure (EF Clif). Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. *J Hepatol*. 2019 Mar; 70(3):398-411
33. Clària J, Moreau R, Fenaille F, Amorós A, Junot C, Gronbaek H, Coenraad MJ, Pruvost A, Ghetas A, Chu-Van E, López-Vicario C, Oettl K, Caraceni P, **Alessandria C**, Trebicka J, Pavesi M, Deulofeu C, Albillos A, Gustot T, Welzel TM, Fernández J, Stauber RE, Saliba F, Butin N, Colsch B, Moreno C, Durand F, Nevens F, Bañares R, Benten D, Ginès P, Gerbes A, Jalan R, Angeli P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL Clif Consortium Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif). Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis. *Hepatology*. 2019 Apr;69(4):1686-1701
34. Piano S, Singh V, Caraceni P, Maiwall R, **Alessandria C**, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, de Cassia Ribeiro Barea R, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Wong F, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bhamidimarri KR, Boyer TD, Maevskaya M, Fassio E, Kim HS, Hwang JS, Gines P, Gadano A, Sarin SK, Angeli P; International Club of Ascites Global Study Group. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. *Gastroenterology*. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.
35. **Alessandria C**, Caviglia GP, Campion D, Nalbhone F, Sanna C, Musso A, Abate ML, Rizzetto M, Saracco GM, Balzola F. HLA-DQ Genotyping, Duodenal Histology, and Response to Exclusion Diet in Autistic Children With Gastrointestinal Symptoms. *J Pediatr Gastroenterol Nutr*. 2019;69(1):39-44
36. Fernández J, Clària J, Amorós A, Aguilar F, Castro M, Casulleras M, Acevedo J, Duran-Güell M, Nuñez L, Costa M, Torres M, Horrillo R, Ruiz-Del-Árbol L, Villanueva C, Prado V, Arteaga M, Trebicka J, Angeli P, Merli M, **Alessandria C**, Aagaard NK, Soriano G, Durand F, Gerbes A, Gustot T, Welzel TM, Salerno F, Bañares R, Vargas V, Albillos A, Silva A, Morales-Ruiz M, Pavesi M, Jalan R, Bernardi M, Moreau R, Páez A, Arroyo V. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. *Gastroenterology*. 2019 Jul;157(1):149-162
37. Trebicka J, Amorós A, Pitarch C, Titos E, Alcaraz-Quiles J, Schierwagen R, Deulofeu C, Fernandez-Gomez J, Piano S, Caraceni P, Oettl K, Sola E, Laleman W, McNaughtan J, Mookerjee RP, Coenraad MJ, Welzel T, Steib C, Garcia R, Gustot T, Rodriguez Gandia MA, Bañares R, Albillos A, Zeuzem S, Vargas V, Saliba F, Nevens F, **Alessandria C**, de Gottardi A, Zoller H, Ginès P, Sauerbruch T, Gerbes A, Stauber RE, Bernardi M, Angeli P, Pavesi M, Moreau R, Clària J, Jalan R, Arroyo V. Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. *Front Immunol*. 2019 Mar 19;10:476. doi: 10.3389/fimmu.2019.00476. eCollection 2019
38. Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, **Alessandria C**. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. *World J Hepatol*. 2019 Jun 27;11(6):489-512. doi: 10.4254/wjh.v11.i6.489. Review.
39. Fernández J, Angeli P, Trebicka J, Merli M, Gustot T, **Alessandria C**, Aagaard NK, de Gottardi A, Welzel TM, Gerbes A, Soriano G, Vargas V, Albillos A, Salerno F, Durand F, Bañares R, Stauber R, Prado V, Arteaga M, Hernández-Tejero M, Aziz F, Morando F, Jansen C, Lattanzi B, Moreno C, Campion D, Gronbaek H, Garcia R, Sánchez C, García E, Amorós A, Pavesi M, Clària J, Moreau R, Arroyo V. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. *Clin Gastroenterol Hepatol*. 2020 Apr;18(4):963-973
40. Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, Zaccherini G, **Alessandria C**, Angeli P, Bernardi M, Beuers U, Caraceni P, Durand F, Mookerjee RP, Trebicka J, Vargas V, Andrade RJ, Carol M, Pich J, Ferrero J, Domenech G, Llopis M, Torres F, Kamath PS, Abraldes JG, Solà E, Ginès P. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Gastroenterol Hepatol*. 2020 Jan;5(1):31-41

41. Moreau R, Clària J, Aguilar F, Fenaille F, Lozano JJ, Junot C, Colsch B, Caraceni P, Trebicka J, Pavesi M, **Alessandria C**, Nevens F, Saliba F, Welzel TM, Albillos A, Gustot T, Fernández J, Moreno C, Baldassarre M, Zaccherini G, Piano S, Montagnese S, Vargas V, Genescà J, Solà E, Bernal W, Butin N, Hautbergue T, Cholet S, Castelli F, Jansen C, Steib C, Campion D, Mookerjee R, Rodríguez-Gandía M, Soriano G, Durand F, Benten D, Bañares R, Stauber RE, Gronbaek H, Coenraad MJ, Ginès P, Gerbes A, Jalan R, Bernardi M, Arroyo V, Angeli P; CANONIC Study Investigators of the EASL Clif Consortium; Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EF Clif). Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. *J Hepatol.* 2020 Apr;72(4):688-701.
42. Fabrellas N, Carol M, Palacio E, Aban M, Lanzillotti T, Nicolao G, Chiappa MT, Esnault V, Graf-Dirmeier S, Helder J, Gossard A, Lopez M, Cervera M, Dols LL; LiverHope Consortium Investigators. Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. *Hepatology.* 2020 Mar;71(3):1106-1116.
43. Trieb M, Rainer F, Stadlbauer V, Douschan P, Horvath A, Binder L, Trakaki A, Knuplez E, Scharnagl H, Stojakovic T, Heinemann Á, Mandorfer M, Paternostro R, Reiberger T, Pitarch C, Amorós A, Gerbes A, Caraceni P, **Alessandria C**, Moreau R, Clària J, Marsche G, Stauber RE. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. *J Hepatol.* 2020 Jul;73(1):113-120
44. Uschner FE, Glückert K, Paternostro R, Gnad T, Schierwagen R, Mandorfer M, Magdaleno F, Ortiz C, Schwarzkopf K, Kamath PS, **Alessandria C**, Boesecke C, Pfeifer A, Reiberger T, Kreisel W, Sauerbruch T, Ferlitsch A, Trebicka J, Klein S. Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. *Liver Int.* 2020 Sep;40(9):2228-2241
45. Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solè C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Özdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Curto A, Pitarch C, Putignano A, Moreno E, Shawcross D, Aguilar F, Clària J, Ponzo P, Jansen C, Vitalis Z, Zaccherini G, Balogh B, Vargas V, Montagnese S, **Alessandria C**, Bernardi M, Ginès P, Jalan R, Moreau R, Angeli P, Arroyo V; PREDICT STUDY group of the EASL-CLIF Consortium. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. *J Hepatol.* 2020 Oct;73(4):842-854.
46. Wong F, Piano S, Singh V, Bartoletti M, Maiwall R, **Alessandria C**, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, de Cassia Ribeiro Barea R, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bruns T, Yoon EL, Giralá M, Pysropoulos NT, Kim TH, Yim SY, Juanola A, Gadano A, Angeli P; International Club of Ascites Global Study Group. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. *J Hepatol.* 2021 Feb;74(2):330-339.
47. Caraceni P, Tufoni M, Zaccherini G, Riggio O, Angeli P, **Alessandria C**, Neri S, Foschi FG, Levantesi F, Airoldi A, Simone L, Svegliati-Baroni G, Fagioli S, Laffi G, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Gasbarrini A, De Marco R, Piano S, Nardelli S, Elia C, Roncadori A, Baldassarre M, Bernardi M; ANSWER Study Investigators. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. *J Hepatol.* 2021 Feb;74(2):340-349.
48. Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, **Alessandria C**, Beuers U, Caraceni P, Francoz C, Mookerjee R, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernández R, Korenjak M, Watson H, Abralde JG, Kamath P, Ginès P; LiverHope Consortium Investigators. ENDPOINTS AND DESIGN OF CLINICAL TRIALS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: POSITION PAPER OF THE LIVERHOPE CONSORTIUM. *J Hepatol.* 2021 Jan;74(1):200-219.
49. Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia-Lopez E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Praktijnjo M, Curto A, Pitarch C, Putignano A, Moreno E, Bernal W, Aguilar F, Clària J, Ponzo P, Vitalis Z, Zaccherini G, Balogh B, Gerbes A, Vargas V, **Alessandria C**, Bernardi M, Ginès P, Moreau R, Angeli P, Jalan R, Arroyo V; PREDICT STUDY group of the EASL-CLIF CONSORTIUM. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. *J Hepatol.* 2021 May;74(5):1097-1108.
50. Caraceni P, Vargas V, Solà E, **Alessandria C**, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The use of Rifaximin in Patients with Cirrhosis. *Hepatology.* 2021 Sep;74(3):1660-1673.

51. Roma M, Bonetto S, Giovo I, Campion D, Rizzi F, Peroni CL, Saracco GM, **Alessandria C**. Liver involvement in adult-onset Still's disease: our experience in a third level liver unit and review of the literature. *Minerva Gastroenterology* 2021 May 12. doi: 10.23736/S2724-5985.21.02897-7
52. Gustot T, Stadlbauer V, Laleman W, **Alessandria C**, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. *J Hepatol.* 2021 Jul;75 Suppl 1:S36-S48
53. Morelli MC, Rendina M, La Manna G, **Alessandria C**, Pasulo L, Lenci I, Bhoori S, Messa P, Biancone L, Gesualdo L, Russo FP, Petta S, Burra P; Italian Association for the Study of Liver, and the Italian Society of Nephrology. Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). *Dig Liver Dis.* 2021 Jun;53 Suppl 2:S49-S86.
54. Ponzio P, Campion D, Rizzo M, Roma M, Caviglia GP, Giovo I, Rizzi F, Bonetto S, Saracco GM, **Alessandria C**. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. *Dig Liver Dis.* 2022 Aug;54(8):1101-1108
55. Pose E, Solà E, Lozano JJ, Juanola A, Sidorova J, Zaccherini G, de Wit K, Uschner F, Tonon M, Kazankov K, Jiménez C, Campion D, Napoleone L, Ma AT, Carol M, Morales-Ruiz M, **Alessandria C**, Beuers U, Caraceni P, Francoz C, Durand F, Mookerjee RP, Trebicka J, Vargas V, Piano S, Watson H, Abralde JG, Kamath PS, Davis MM, Ginès P; investigators of the LIVERHOPE Consortium. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. *Hepatol Commun.* 2022; 6(5):1100-1112
56. Campion D, Rizzi F, Bonetto S, Giovo I, Roma M, Saracco GM, **Alessandria C**. Assessment of glomerular filtration rate in patients with cirrhosis: Available tools and perspectives. *Liver Int.* 2022 Nov;42(11):2360-2376
57. Zaccherini G, Baldassarre M, Tufoni M, Nardelli S, Piano S, **Alessandria C**, Neri S, Foschi FG, Levantesi F, Bedogni G, Domenicali M, Bernardi M, Caraceni P; ANSWER Study Investigators. Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database. *Am J Gastroenterol.* 2023 Jan 1;118(1):168-173.
58. Weiss E, de la Peña-Ramirez C, Aguilar F, Lozano JJ, Sánchez-Garrido C, Sierra P, Martin PI, Diaz JM, Fenaille F, Castelli FA, Gustot T, Laleman W, Albillos A, **Alessandria C**, Domenicali M, Caraceni P, Piano S, Saliba F, Zeuzem S, Gerbes AL, Wendon JA, Jansen C, Gu W, Papp M, Mookerjee R, Gambino CG, Jiménez C, Giovo I, Zaccherini G, Merli M, Putignano A, Uschner FE, Berg T, Bruns T, Trautwein C, Zipprich A, Bañares R, Presa J, Genesca J, Vargas V, Fernández J, Bernardi M, Angeli P, Jalan R, Claria J, Junot C, Moreau R, Trebicka J, Arroyo V. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET). *Gut.* 2023 Feb 14;gutjnl-2022-328708. doi: 10.1136/gutjnl-2022-328708. Online ahead of print. PMID: 36788015

Book chapters

1. **Alessandria C**, Balzola F. I disturbi gastrointestinali e l'asse intestino-cervello nei disturbi dello spettro autistico. In: Keller R. "I disturbi dello spettro autistico in adolescenza e in età adulta. Aspetti diagnostici e proposte di intervento". Erickson Editore, 2016: 147-162. ISBN 9788859011163 (<https://www.erickson.it/it/i-disturbi-de-llo-spettro-autistico-in-adolescenza-e-in-eta-adulta>)
2. **Alessandria C**, De Bernardi-Venon W, Martini S, Rizzetto M. Clinica e terapia della cirrosi epatica. In: AAVV "MEDICINA CLINICA Diagnostica e Terapia", vol. II, C.G. Ed. Med. Scient., 2016: 377-396. ISBN 978-88-7110-340-2 (<https://www.cgems.it/Cgems-Prodotti-Dettaglio.asp?Prodotto=749>)

Reviewer activity

Alimentary Pharmacology and Therapeutics
 Frontiers in Pharmacology
 Hepatology International
 Journal of Hepatology

Research Supports/Grants

Site principal investigator: international multicenter study **LIVERHOPE study**. "Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis: a multicentre, double blind, placebo controlled randomized clinical trial". Topic: SC1-PM-09-2016 - New therapies for chronic diseases. Call for proposal: H2020-SC1-2016-RTD. Funding scheme: RIA - Research and Innovation action. EC Contribution: € 5.998.800. Grant agreement number 731875

Site principal investigator for the hospital: international multicenter study **DECISION study** "Decompensated Cirrhosis: Identification of new Combinatorial therapies based on system approaches". Topic: SC1-BHC-02-2019 - Systems approaches for the discovery of combinatorial therapies for complex disorders. Call for proposal: H2020-SC1-2019-Two-Stage-RTD. Funding scheme: RIA - Research and Innovation action. EC Contribution: € 6.000.000. Grant agreement number 847949

Clinical trials - Principal Investigator

1. Site principal investigator: Italian multicenter study **ANSWER Study**. Phase IV randomized Italian multicenter study entitled "The Use of Human Albumin for the Treatment of Ascites in Patients with Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial" sponsored by the Italian Drug Agency (AIFA). 2011-2015. Results published in Lancet. 2018 Jun 16;391(10138):2417-2429 e in J Hepatol. 2021 Feb;74(2):340-349.
2. Site principal investigator: international multicenter study **CANONIC Study**. Observational European multicenter study performed by the EASL-CLIF Consortium on the definition, development and outcome of acute-on-chronic liver failure. 2011. Results published in Gastroenterology. 2013 Jun;144(7):1426-37
3. Site principal investigator: international multicenter study **GLOBAL Study**. The epidemiology and the clinical impact of bacterial infections in hospitalized patients with cirrhosis: a multicenter observational prospective survey among the members of the International Club of Ascites. Prospective international observational study to define the epidemiology of bacterial infections in cirrhosis worldwide. 2015-2016. Results published in Gastroenterology. 2019 Apr;156(5):1368-1380
4. Site principal investigator: international multicenter study **INFECIR-2 Study**. Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality. 2015-2017. Results published in Clin Gastroenterol Hepatol. 2020 Apr;18(4):963-973
5. Site principal investigator: international multicenter study **PREDICT Study**. Protocol of the Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study on behalf of the EASL-CLIF Consortium. 2017-2018. Results published in J Hepatol 2020 Oct;73(4):842-854 and in J Hepatol. 2021 May;74(5):1097-1108
6. Site principal investigator: international multicenter study **LIVERHOPE study**. Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis: a multicentre, double blind, placebo controlled randomized clinical trial. 2017-ongoing. Results published in Lancet Gastroenterol Hepatol. 2020 Jan;5(1):31-41 and in Hepatol Commun. 2022 May;6(5):1100-1112.

7. Site principal investigator for the hospital: international multicenter study **DECISION study** "Decompensated Cirrhosis: Identification of new Combinatorial therapies based on system approaches". 2020-ongoing.
8. Site principal investigator: international multicenter study **GLOBAL-AKI study** "Characteritics and management of acute kidney injury in hospitalized patients with cirrhosis: a multicenter intercontinental observational prospective study". 2022-ongoing.

Governing boards, steering committees, scientific committees

- Member of the Scientific Committee of the International Club of Ascites (2011-2013)
- Member of the Steering Committee of the European Foundation for the study of chronic liver failure (EF-CLIF, 2019-ongoing)

In compliance with the GDPR and Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned Decree.

Turin, March 21st 2023

Dr. Carlo Alessandria

